---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-031603"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:33:41.904534+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aditxt regains Nasdaq minimum bid price compliance, removes panel monitoring

## Summary
- Regained full compliance with Nasdaq listing requirements; no longer under panel monitoring.
- Adimune subsidiary targeting IND/CTA filing for human trials in Q3/Q4 2025 for psoriasis and Type 1 diabetes.
- Pearsanta plans commercial launch of prostate cancer and endometriosis tests in H2 2025.
- Working to close Appili and Evofem acquisitions; capital and restructuring needed.
- CEO reports approximately 40,000-50,000 shareholders globally.

## SEC filing metadata
- accession: 0001213900-25-031603
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025031603/0001213900-25-031603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025031603/ea0238058-8k_aditxtinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-031603
- JSON: https://secwatch.observer/filing/0001213900-25-031603.json
- Plain text: https://secwatch.observer/filing/0001213900-25-031603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.